Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II Reactions: Acetylation Reactions
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 3, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Jason M Walraven1, Yu Zang, John O Trent
1Department of Pharmacology & Toxicology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA.
Genetic variations in Arylamine N-acetyltransferase 2 (NAT2) affect drug metabolism and cancer risk. This study uses the human NAT2 crystal structure to analyze how these genetic changes impact protein function, improving understanding of drug responses and carcinogen detoxification.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: